Resumption of migraine preventive treatment with CGRP(-receptor) antibodies after a 3-month drug holiday: a real-world experience

BACKGROUND: Migraine frequency increases after the cessation of successful preventive treatment with CGRP(-receptor) monoclonal antibodies (mAbs). In this study, we aimed to evaluate the course of migraine after treatment resumption. METHODS: Patients with migraine, who started treatment with the sa...

Descripción completa

Detalles Bibliográficos
Autores principales: Raffaelli, Bianca, Terhart, Maria, Mecklenburg, Jasper, Neeb, Lars, Overeem, Lucas Hendrik, Siebert, Anke, Steinicke, Maureen, Reuter, Uwe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8966337/
https://www.ncbi.nlm.nih.gov/pubmed/35350990
http://dx.doi.org/10.1186/s10194-022-01417-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8966337/
https://www.ncbi.nlm.nih.gov/pubmed/35350990
http://dx.doi.org/10.1186/s10194-022-01417-9

Ejemplares similares